Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2024-10.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Experiences of and barriers to transition-related healthcare among Korean transgender adults: focus on gender identity disorder diagnosis, hormone therapy, and sex reassignment surgery
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Epidemiol Health > Volume 40; 2018 > Article
Original Article
 Experiences of and barriers to transition-related healthcare among Korean transgender adults: focus on gender identity disorder diagnosis, hormone therapy, and sex reassignment surgery
Hyemin Lee1orcid, Jooyoung Park1orcid, Bokyoung Choi1orcid, Horim Yi1orcid, Seung-Sup Kim1,2orcid
Epidemiol Health 2018;40:e2018005.
DOI: https://doi.org/10.4178/epih.e2018005
Published online: February 27, 2018

1Department of Public Health Sciences, Graduate School of Korea University, Seoul, Korea

2Department of Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA, USA

Correspondence: Seung-Sup Kim Department of Public Health Sciences, Graduate School of Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea E-mail: ssk3@korea.ac.kr
• Received: November 29, 2017   • Accepted: February 27, 2018

©2018, Korean Society of Epidemiology

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 32,064 Views
  • 452 Download
  • 36 Web of Science
  • 37 Crossref
  • 38 Scopus
Full Article

Download PDF Download PDF

  • OBJECTIVES
    Transgender people may encounter barriers to transition-related healthcare services. This study aimed to investigate the experiences of transition-related healthcare and barriers to those procedures among transgender adults in Korea.
  • METHODS
    In 2017, we conducted a nationwide cross-sectional survey of 278 transgender adults, which named Rainbow Connection Project II, in Korea. We assessed the prevalence of transition-related healthcare, including gender identity disorder (GID) diagnosis, hormone therapy, and sex reassignment surgery. To understand the barriers to those procedures, we also asked participants for their reasons for not receiving each procedure. Further, this study examined their experiences of and the reasons for using non-prescribed hormone medications.
  • RESULTS
    Of transgender people participated in the survey, 91.0% (n=253/278) were diagnosed with GID, 88.0% (n=243/276) received hormone therapy, and 42.4% (n=115/271) have had any kind of sex reassignment surgery. Cost was the most common barrier to transition-related healthcare among Korean transgender adults. Other common barriers were identified as follows: negative experiences in healthcare settings, lack of specialized healthcare professionals and facilities, and social stigma against transgender people. Among those who had taken hormone medications, 25.1% (n=61/243) reported that they had ever purchased them without a prescription.
  • CONCLUSIONS
    Our findings suggest that barriers to transition-related healthcare exist in Korea and constrain transgender individuals’ safe access to the needed healthcare. Institutional interventions are strongly recommended to improve access to transition-related healthcare. These interventions include provision of programs to train Korean healthcare professionals and expansion of national health insurance to include these procedures.
  • Keywords: Transgender persons, Health services for transgender persons, Sex reassignment surgery, Sexual and gender minorities, Gender identity, Republic of Korea
Transgender people have a gender identity or expression that is inconsistent with their legal sex at birth [1,2]. Transgender individuals can be classified as transwoman, transman, non-binary transgender person, etc. Non-binary transgender people refer to those who do not identify themselves as either man or woman [3]. Unlike transgender individuals, cisgender people have a gender identity or expression that matches their legal sex at birth [4].
In the US, prevalence of the transgender population was estimated to be 390 per 100,000 individuals [5]. This estimation is based on a meta-analysis of 12 national surveys using three databases in 2017, so the results address problems in previous studies resulting from non-probability sampling and representativeness estimating the transgender population size. By extrapolating the estimated frequency of transgender individuals from the meta-analysis study to the total Korean population, which is 51,635,256 as of February 2018 [6], there are an estimated 201,377 transgender individuals in Korea.
Through gender transition, transgender people live their lives with the gender expression or presentation that affirms their gender identity [7]. When medically necessary, many transgender individuals undergo transition-related healthcare or medical transition, including gender identity disorder (GID) diagnosis, hormone therapy, and sex reassignment surgery [7]. Transition-related healthcare can alleviate gender dysphoria and improve physical and mental health as well as quality of life among transgender people [8-10]. Although not all transgender individuals receive hormone therapy or sex reassignment surgery [7,11], transition-related healthcare is a salient factor for transgender people’s health and wellbeing [4].
In Korea, access to transition-related healthcare is critical not only for reducing transgender individuals’ own gender dysphoria, but also for institutional factors, such as legal sex change and exemption from military service [7,11]. Legal sex change is based on “The Guidelines for the Handling of Petition for Legal Sex Change Permit of Transgender People” in Article 435 of the Supreme Court Family Relation Registration Regulation in Korea [12,13]. The regulation requires applicants to receive a psychiatric diagnosis of GID, remove reproductive capacity, and have sex reassignment surgery through investigative matters and compulsory documentation.
Further, all individuals whose legal sex is male and who have Korean nationality are obliged to serve in military services, as mandated by the Military Service Act and Article 39 (1) of the Constitution of Korea. This obligation also applies to transwomen who do not change their legal sex at birth [14,15]. Under such circumstances, transwomen who wish to be exempt from military service must obtain a GID diagnosis, receive hormone therapy, and even undergo sex reassignment surgery [11,14,15]. Transmen are also required to have a physical examination for military service after changing their legal sex to male [14].
However, the Korean healthcare system and policies related to transition-related healthcare are not well established [7,11]. Standard curricula for educating and training healthcare professionals do not include transition-related healthcare, and few training manuals or guidelines present this information. Further, transgender individuals are burdened with the entire cost of hormone therapy and sex reassignment surgery because those medical procedures are not covered by national health insurance.
Research on the experiences of and barriers to transition-related healthcare among transgender people is also lacking in Korea. Only 22 out of 128 studies on the health of lesbian, gay, bisexual, and transgender people that published before 2013 included trans2gender people, and most were case reports of transgender patients or clinical studies introducing methods for sex reassignment surgery [16]. Besides hospital-based clinical studies, research regarding the experiences of transition-related healthcare among transgender people is limited to only a single qualitative study in 2017 [11].
This study aimed to investigate the experiences of and barriers to transition-related healthcare, including GID diagnosis, hormone therapy, and sex reassignment surgery, for transgender adults in Korea. In addition, this study examined the experiences of non-prescribed hormone use and the reasons for that use to identify unsafe practices regarding transition-related healthcare among Korean transgender people.
Data and study population
This study conducted a nationwide cross-sectional survey of Korean transgender adults to explore their experiences of transition-related healthcare and the barriers to those procedures. Participants were ≥19 years old and self-identified as either: 1) transwoman, 2) transman, or 3) non-binary transgender person with the experiences of transition-related healthcare. Because non-binary transgender people also undergo transition-related healthcare based on institutional factors as well as medical treatments for relieving gender dysphoria [11], they were also included in the study.
Data were collected through an online-based survey from June 27 to August 31, 2017. To advertise the survey and recruit study participants, this study utilized Korea Queer Festivals held in Seoul and Daegu, four healthcare institutions in Seoul that provide transition-related healthcare for transgender patients, and three online/offline transgender communities. Informed consent for participating in the survey and using the data for academic purposes was collected from all respondents. As compensation for participation, all respondents were rewarded 10,000 Korean won (KRW). This study protocol was approved by the institutional review board of Korea University (no. 1040548-KU-IRB-17-67-A-1).
A total of 347 transgender adults participated in the survey. Among them, there were 5 respondents who did not consent to academic use of the study, 62 respondents who did not provide demographic information including age and gender identity, and 2 respondents who did not respond to the question about GID diagnosis. After excluding those respondents, the final study population consisted of 278 transgender individuals.
Measurement
Questionnaires were used to collect information on the experiences of transition-related healthcare, access to healthcare, health status, etc. Participants answered approximately 160-230 questions, including several additional questions depending on their gender identity and experiences of transition-related healthcare.
Regarding respondents’ gender identity, this study assessed both legal sex at birth and current gender identity to classify those with mismatching legal sex at birth and current gender identity as transgender people and those with matching identities as cisgender people (Table 1) [17]. Among transgender respondents, those whose legal sex at birth was male and currently identifying as woman were classified as transwomen, whereas those whose legal sex at birth was female and currently identifying as man were classified as transmen. Respondents who identified as neither man nor woman were categorized as non-binary transgender people. In this study, non-binary transgender individuals and transwomen whose legal sex at birth were male were classified as transfeminine, whereas non-binary transgender individuals and transmen whose legal sex at birth were female were classified as transmasculine [4].
Age, sexual orientation, and residential area were collected as demographic characteristics. Age was dichotomized as 19-29 years or 30-50 years. Respondents’ sexual orientation was classified as homosexual, bisexual, heterosexual, or asexual. Residential area was categorized into three categories (Seoul metropolitan city, other metropolitan cities, or other cities and counties). Respondents also provided information on socioeconomic status, such as educational level (≤high school graduate, college graduate, university graduate, or ≥graduate school graduate), annual household income (<10,000,000, 10,000,000-19,990,000, 20,000,000-29,990,000, 30,000,000-49,990,000, or ≥50,000,000 KRW), and employment status (unemployed, non-precarious employment, precarious employment, self-employed, or unpaid family worker). In addition, respondents reported the route to participating in the survey.
We classified transition-related healthcare into psychiatric diagnosis for GID, hormone therapy, and sex reassignment surgery. For GID diagnosis, respondents answered the question, “Have you ever received a psychiatric diagnosis for GID based on the Korean Standard Classification of Diseases?” Those who did not seek a GID diagnosis were asked to report the reasons why, and multiple choices could be selected.
Hormone therapy was measured with the question, “Are you currently receiving hormone therapy?” Response options were: “I am currently receiving hormone therapy”; “I received hormone therapy, but not currently”; “I never receive hormone therapy, but I want to (or plan to) sometime later”; “I am not sure whether I want to receive hormone therapy”; or “I do not want to receive hormone therapy”. Respondents who chose “I am currently receiving hormone therapy” or “I received hormone therapy, but not currently” were classified as those having experienced hormone therapy, and they were asked to respond to a follow-up question about purchasing non-prescribed hormone medications. For those who have purchased non-prescribed hormone medications, they were asked to report the route of access and the reasons why. In addition, respondents who did not receive hormone therapy were asked to identify the reasons why. Multiple responses could be selected for the questions regarding the route of and the reasons for purchasing hormone medications without a prescription and the reasons for not receiving hormone therapy.
Regarding sex reassignment surgery, respondents were asked whether they have had at least one surgical procedure related to transition. For those who did not have such surgery, additional questions were asked about the reasons why, and multiple choices could be selected.
This study also measured the costs of GID diagnosis and sex reassignment surgery. Regarding the cost of GID diagnosis, respondents chose a response from 0 to 1 million KRW. Since the total cost of hormone therapy varies with the duration of partaking in the therapy, an average cost was not presented. Sex reassignment surgery was classified into breast/chest surgery, genital removal surgery, genital reconstruction surgery, facial surgery, voice surgery (only for transfeminine respondents), and other surgeries. For the cost of sex reassignment surgery, respondents responded from 1 to 50 million KRW, with suggestions of the average cost and standard deviation. Additionally, respondents reported their experiences of delaying or avoiding hospital visits and being denied healthcare services within the past 12 months.
Statistical analysis
This study analyzed the experiences and barriers that transgender people faced during transition-related healthcare with descriptive statistics, and the results were stratified by participants’ gender identity. All statistical analyses were performed using Stata/SE version 13.0 (StataCorp., College Station, TX, USA).
Socio-demographic characteristics and experiences of transition-related healthcare
Among the total study population, 173 (62.2%) were transfeminine and 105 (37.8%) were transmasculine. Of all respondents, 218 (78.4%) were 19-29 years and 60 (21.6%) were 30-50 years old, indicating that the majority were in their 20s (Table 2). Regarding sexual orientation and educational level, heterosexual (n=129/278, 46.4%) and university graduate (n=145/254, 57.1%) were the most frequent responses. Approximately half of respondents reported an annual household income of <10,000,000 (n=69/252, 27.4%) and 10,000,000-19,990,000 KRW (n=53/252, 21.0%). More than three-quarters of respondents were unemployed (n=118/253, 46.6%) or precarious employees (n=78/253, 30.8%), and a majority resided in metropolitan cities. Most respondents participated in the survey through four healthcare institutions (n=130/278, 46.8%) and online/offline transgender communities (n=126/278, 45.3%).
Among 278 transgender adults, 253 (91.0%) had been diagnosed with GID (Table 3). Meanwhile, 243 of 276 respondents (88.0%) who answered the question about hormone therapy were receiving or had previously received hormone therapy, and 115 of 271 respondents (42.4%) who answered the question about sex reassignment surgery have had at least one of transition-related surgery. The prevalence of a GID diagnosis was significantly higher in the transfeminine group (n=164/173, 94.8%) and 30-50-year-old group (n=59/60, 98.3%) than in the transmasculine group (n=89/105, 84.8%) and 19-29-year-old group (n=194/218, 89.0%). The prevalence of hormone therapy also was significantly higher in the transfeminine group (n=160/171, 93.6%) and 30-50-year-old group (n=58/59, 98.3%) than in the transmasculine group (n=83/105, 79.0%) and 19-29-year-old group (n=185/217, 85.3%). However, the prevalence of sex reassignment surgery was significantly higher in the transmasculine group (n=58/103, 56.3%) compared to the transfeminine group (n=57/168, 33.9%).
Barriers to transition-related healthcare
A majority of transfeminine (n=164/173, 94.8%) and transmasculine (n=89/105, 84.8%) individuals reported that they were diagnosed with GID (Table 4). Among these 25 individuals who did not receive a GID diagnosis, 12 (48.0%) answered, “I was having financial difficulties”.
Among 276 respondents, 225 (81.5%) reported that they were currently receiving hormone therapy (Table 5). In terms of gender identity, 150 of 171 transfeminine (87.7%) and 75 of 105 transmasculine (71.4%) individuals were currently receiving hormone therapy. Those who were not currently receiving hormone therapy (n=51/276, 18.5%) were asked about the reasons for not receiving or discontinuing the therapy, and the most common response was “I was having financial difficulties” (n=28/51, 54.9%).
Among the 243 respondents who had ever received hormone therapy, 61 (25.1%) reported that they had ever purchased non-prescribed hormone medications (Table 6). Those who had purchased non-prescribed hormone medications were asked about the purchasing route of such medications, and the most common response was “over-the-counter medicines” (n=28/61, 45.9%), which is similar to contraceptives. With respect to reasons for purchasing non-prescribed hormone medications, the most common response was “I did not have a diagnosis from a psychiatrist” (n=34/61, 55.7%).
A total of 115 among 271 transgender respondents reported that they had undergone at least one kind of sex reassignment surgery, including 57 of 168 transfeminine (33.9%) and 58 of 103 transmasculine (56.3%) individuals (Table 7). Among 271 respondents, 156 (57.6%) did not have any kind of sex reassignment surgery. The most common reason why they did not have such surgery was “The surgery was too costly” (n=122/156, 78.2%).
This study analyzed cross-sectional data of 278 transgender adults to investigate the experiences of and barriers to transition-related healthcare in Korea. The results suggest that 91.0% of surveyed transgender adults were diagnosed with GID, 88.0% had received hormone therapy, and 42.4% had undergone at least one kind of transition-related surgery. The primary reason for not accessing transition-related healthcare was due to the cost of such procedures. This study additionally analyzed the cost that participants paid for transition-related healthcare (Appendix 1). A majority (n=170, 67.7%) reported that they paid 250,000-490,000 KRW for a GID diagnosis. The average cost of each kind of sex reassignment surgery was calculated and classified by respondents’ gender identity. These results indicated that genital reconstruction surgery was the biggest financial burden for transgender respondents, estimated at an average of 15,148,000 KRW for transfeminine and 20,571,000 KRW for transmasculine individuals.
Along with the high costs of medical transition, prejudice and discrimination of healthcare professionals towards transgender individuals were primary factors limiting use of transition-related healthcare. This study further analyzed respondents’ experiences of delaying or avoiding hospital visits and being denied services by healthcare professionals (Appendix 2). Among 262 participants, 112 (42.7%) reported that they themselves had delayed or avoided hospital visits, and 14 (5.3%) reported that they were denied healthcare services within the past 12 months. According to a previous survey about discrimination based on sexual orientation and gender identity in Korea, 28 of 78 transgender respondents (35.9%) who visited healthcare institutions within the past 5 years reported that they experienced discrimination from healthcare professionals [18].
Another barrier to transition-related healthcare was based on the limited knowledge of healthcare professionals on medical transition and the lack of healthcare institutions that can provide such procedures. Among the 25 transgender participants who did not receive a GID diagnosis, 28.0% responded that “I could not find a psychiatrist who would provide an adequate diagnosis.” Since GID diagnosis is required to receive hormone therapy and sex reassignment surgery in the majority of cases, the diagnosis plays an essential role in determining access to medical transition [19]. Among respondents who did not receive hormone therapy, 33.3% reported a reason of “I did not have a medical certificate from a psychiatrist” and 15.7% reported a reason of “I did not have access to healthcare facilities that provided hormone therapy”.
The World Professional Association for Transgender Health has published “Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People,” providing a clinical guideline for transition-related healthcare [2]. In North American and European countries, education and training programs on medical transition for healthcare professionals have been developed in healthcare institutions and academic societies [7]. Moreover, previous studies indicate that educating and training medical students about transition-related healthcare strengthens their competency as healthcare professionals with respect to knowledge, attitude, and skills regarding transgender health [20,21]. Since Korean medical schools do not educate about medical transition, healthcare professionals have relatively little knowledge about such procedures [7].
Negative social perception towards transgender people was another barrier that may inhibit these individuals from accessing transition-related healthcare. Participants provided the following reasons for not receiving hormone therapy: “I believed it would raise difficulties in my economic activities such as finding employment and working” (47.1%), “I was worried about potential stigma from other people around me” (25.5%), and “My family and/or friends advised against it” (15.7%). Those who did not have sex reassignment surgery also responded with the following reasons: “I believed it would raise difficulties in my economic activities such as finding employment and working” (36.5%), “My family and/or friends advised against it” (25.0%), and “I was worried about potential stigma from other people around me” (20.5%). Transgender individuals could experience difficulties in economic activities, such as getting a job or maintaining a career, due to medical transition experiences. Further, family members and friends of transgender individuals may oppose their medical transition.
Our results indicate that transgender people encountered barriers to accessing transition-related healthcare due to financial burden, negative experiences in healthcare settings, lack of specialized healthcare professionals and medical facilities, and social stigma against transgender individuals in Korea. These barriers could contribute to unsafe practices regarding transition-related healthcare [22,23]. In this study, 25.1% of 243 transgender participants reported purchasing non-prescribed hormone medications. They used over-the-counter medicines that contained hormonal components or purchased hormone drugs through domestic or foreign online vendors/suppliers or acquaintances/friends. For patient safety, healthcare professionals should control the dose of hormone therapy depending on the health condition of the transgender individual, and regular clinical follow-ups also are essential in hormone therapy. Therefore, self-prescribed hormone medications can be hazardous because the side effects, such as thromboembolism or elevated liver enzymes, may not be identified or appropriately treated [7,23].
To improve access to transition-related healthcare for transgender populations, national health insurance coverage should be expanded for such procedures. Among 118 nations, 45 countries pay for the costs of at least one kind of medical transition through national health insurance or public healthcare system [7]. Currently, the Korean public healthcare system does not cover the costs of hormone therapy or sex reassignment surgery for transgender people. Considering that expanding health insurance coverage could be an institutional intervention to relieve the financial burden of transition-related healthcare, more active discussions on this topic should be facilitated.
A noteworthy limitation of this study is that respondents may not accurately represent the whole transgender population in Korea. However, the population size is unknown because no studies have identified the transgender population size as of May 2018 in Korea [7,16]. We tried to recruit the maximum number of transgender individuals from healthcare institutions, Korea Queer Culture Festivals, and online/offline transgender communities through convenience sampling. Nonetheless, such data collection strategies may influence and potentially bias the study’s findings. Among 278 transgender respondents, 46.8% participated through healthcare institutions, whereas 45.3 and 7.9% became involved through online/offline transgender communities and the Korea Queer Culture Festivals, respectively. The number of respondents from healthcare institutions who had received a GID diagnosis or hormone therapy was relatively higher than that of respondents from online/offline transgender communities and the Korea Queer Culture Festivals. We cannot exclude the possibility that the experiences of respondents from healthcare institutions who received a GID diagnosis or hormone therapy may be overrepresented. In addition, the majority of respondents (78.4%) were in their 20s, which may be attributed to use of an online-based survey. Consequently, the findings of this study should be cautiously interpreted.
Despite these limitations, the present study also has key strengths. First, this study included the largest number of transgender participants in Korea as of May 2018, since all available methods was fully utilized to collect data. Second, this is the first academic research to identify the experiences of and barriers to transition-related healthcare of Korean transgender adults. Considering our findings, future research should continue to examine the health of the transgender population in Korea.
In conclusion, transition-related healthcare is medically necessary for transgender individuals to alleviate their gender dysphoria. Also, it is a legal prerequisite to change their gender identity on official documents and a method to protect themselves against social violence and discrimination and to access sex-segregated facilities, such as public toilets [19]. Therefore, expansions of health insurance coverage to include medical transition is needed to improve access to such medical procedures and support the health of transgender people. In addition, education and training programs for healthcare professionals should be institutionalized to ensure that they can provide appropriate transition-related healthcare services to transgender people. Beyond the healthcare setting, additional discussions are needed to improve social acceptance and recognition of transgender population and reduce stigma and discrimination against them. We strongly recommend that government-conducted nationwide surveys should include questions about respondents’ gender identity to promote future research on the health of transgender people. Lastly, based on our findings about barriers to transition-related healthcare, implementation of institutional intervention is urgently required to improve the health of Korean transgender individuals.
This work was supported through Daum storyfunding “Our Transgender Health Study Journey Begins”. This work was also supported by Engineers and Scientists for Change as its first crowdfunding project. The authors also thank healthcare professionals from the four healthcare institutions, social activists from Korean Transgender Rights Organization Jogakbo, and consultants for their assistance with survey development and promotion. In addition, the authors deeply appreciate our participants in this study.

The authors have no conflicts of interest to declare for this study.

Supplementary Material: Korean version is available at http://www.e-epih.org/.
epih-40-e2018005-supplementary.pdf
Table 1.
Gender identity measured with a two-step method1
Current gender identity Legal sex at birth
Male Female
Man Cisgender2 Transmasculine
Woman Transfeminine Cisgender2
Do not identify as man or woman Transfeminine Transmasculine

1 Modified from Reisner et al. Lancet 2016;388:412-436 [4].

2 Cisgender defined as a non-transgender whose legal sex at birth is in accordance with their current gender identity.

Table 2.
Distribution of study population and prevalence of gender identity spectrum by socio-demographic characteristics among transgender adults in Korea
All respondents (n=278) Gender identity spectrum1
 p-value2
Transfeminine (n=173) Transmasculine (n=105)
Age (yr) <0.001
 19-29 218 (78.4) 124 (56.9) 94 (43.1)
 30-50 60 (21.6) 49 (81.7) 11 (18.3)
Sexual orientation 0.001
 Heterosexual 129 (46.4) 65 (50.4) 64 (49.6)
 Homosexual 29 (10.4) 24 (82.8) 5 (17.2)
 Bisexual 96 (34.5) 66 (68.8) 30 (31.3)
 Asexual 24 (8.6) 18 (75.0) 6 (25.0)
Educational level3 0.87
 ≤High school graduate 57 (22.4) 34 (59.7) 23 (40.4)
 College graduate 39 (15.4) 25 (64.1) 14 (35.9)
 University graduate 145 (57.1) 86 (59.3) 59 (40.7)
 ≥Graduate school graduate 13 (5.1) 9 (69.2) 4 (30.8)
Annual household income (104 KRW) 0.24
 <1,000 69 (27.4) 48 (69.6) 21 (30.4)
 1,000-1,999 53 (21.0) 30 (56.6) 23 (43.4)
 2,000-2,999 45 (17.9) 30 (66.7) 15 (33.3)
 3,000-4,999 43 (17.1) 25 (58.1) 18 (41.9)
 ≥5,000 42 (16.7) 21 (50.0) 21 (50.0)
Employment status3 0.42
 Unemployed 118 (46.6) 69 (58.5) 49 (41.5)
 Non-precarious employment 45 (17.8) 28 (62.2) 17 (37.8)
 Precarious employment 78 (30.8) 48 (61.5) 30 (38.5)
 Self-employed 11 (4.3) 9 (81.8) 2 (18.2)
 Unpaid family worker 1 (0.4) 0 (0.0) 1 (100.0)
Residential area3 0.95
 Seoul metropolitan city 104 (40.8) 62 (59.6) 42 (40.4)
 Other metropolitan cities4 42 (16.5) 26 (61.9) 16 (38.1)
 Other cities and counties 109 (42.7) 67 (61.5) 42 (38.5)
Data collection 0.33
 Healthcare institutions 130 (46.8) 79 (60.8) 51 (39.2)
 Korea Queer Culture Festivals (Seoul, Daegu) 22 (7.9) 11 (50.0) 11 (50.0)
 Online/offline transgender communities 126 (45.3) 83 (65.9) 43 (34.1)

Values are presented as number (%).

KRW, Korean won.

1 Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

2 p-value of the chi-square test comparing prevalence of gender identity spectrum across sociodemographic groups.

3 Not all study participants provided this information; Number of non-responses: educational level (n=24), annual household income (n=26), employment status (n=25), and residential area (n=23).

4 Included Sejong metropolitan autonomous city.

Table 3.
Distribution of study population and prevalence of transition-related healthcare by socio-demographic characteristics among transgender adults in Korea
Transition-related healthcare
GID diagnosis (n=278)
 Hormone therapy (n=276)
 Sex reassignment surgery (n=271)
Respondents who were diagnosed with GID (n=253)1 Respondents who were not diagnosed with GID (n=25) p-value2 Respondents who received hormone therapy (n=243)3 Respondents who did not receive hormone therapy (n=33) p-value4 Respondents who underwent sex reassignment surgery (n=115)5 Respondents who did not undergo sex reassignment surgery (n=156) p-value6
Gender identity spectrum7 0.005 <0.001 <0.001
 Transfeminine 164 (94.8) 9 (5.2) 160 (93.6) 11 (6.4) 57 (33.9) 111 (66.1)
 Transmasculine 89 (84.8) 16 (15.2) 83 (79.0) 22 (21.0) 58 (56.3) 45 (43.7)
Age (yr) 0.02 0.006 0.71
 19-29 194 (89.0) 24 (11.0) 185 (85.3) 32 (14.7) 90 (41.9) 125 (58.1)
 30-50 59 (98.3) 1 (1.7) 58 (98.3) 1 (1.7) 25 (44.6) 31 (55.4)
Sexual orientation 0.26 0.70 0.001
 Heterosexual 120 (93.0) 9 (7.0) 116 (89.9) 13 (10.1) 68 (54.4) 57 (45.6)
 Homosexual 24 (82.8) 5 (17.2) 23 (82.1) 5 (17.9) 11 (39.3) 17 (60.7)
 Bisexual 86 (89.6) 10 (10.4) 83 (87.4) 12 (12.6) 26 (27.7) 68 (72.3)
 Asexual 23 (95.8) 1 (4.2) 21 (87.5) 3 (12.5) 10 (41.7) 14 (58.3)
Educational level8 0.73 0.88 0.28
 ≤High school graduate 53 (93.0) 4 (7.0) 52 (91.2) 5 (8.8) 19 (33.3) 38 (66.7)
 College graduate 35 (89.7) 4 (10.3) 34 (87.2) 5 (12.8) 17 (43.6) 22 (56.4)
 University graduate 134 (92.4) 11 (7.6) 128 (88.3) 17 (11.7) 68 (46.9) 77 (53.1)
 ≥Graduate school graduate 11 (84.6) 2 (15.4) 11 (84.6) 2 (15.4) 4 (30.8) 9 (69.2)
Annual household income (104 KRW)8 0.38 0.21 0.10
 <1,000 61 (88.4) 8 (11.6) 58 (84.1) 11 (15.9) 26 (37.7) 43 (62.3)
 1,000-1,999 51 (96.2) 2 (3.8) 51 (96.2) 2 (3.8) 29 (54.7) 24 (45.3)
 2,000-2,999 42 (93.3) 3 (6.7) 41 (91.1) 4 (8.9) 17 (37.8) 28 (62.2)
 3,000-4,999 41 (95.3) 2 (4.7) 38 (88.4) 5 (11.6) 14 (32.6) 29 (67.4)
 ≥5,000 37 (88.1) 5 (11.9) 35 (83.3) 7 (16.7) 22 (52.4) 20 (47.6)
Employment status8 0.006 0.002 0.68
 Unemployed 105 (89.0) 13 (11.0) 98 (83.1) 20 (16.9) 54 (45.8) 64 (54.2)
 Non-precarious employment 42 (93.3) 3 (6.7) 42 (93.3) 3 (6.7) 19 (42.2) 26 (57.8)
 Precarious employment 74 (94.9) 4 (5.1) 74 (94.9) 4 (5.1) 29 (37.2) 49 (62.8)
 Self-employed 11 (100.0) 0 (0.0) 11 (100.0) 0 (0.0) 4 (36.4) 7 (63.6)
 Unpaid family worker 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
Residential area8 0.07 0.08 0.02
 Seoul metropolitan city 99 (95.2) 5 (4.8) 96 (92.3) 8 (7.7) 52 (50.0) 52 (50.0)
 Other metropolitan cities9 40 (95.2) 2 (4.8) 39 (92.9) 3 (7.1) 21 (50.0) 21 (50.0)
 Other cities and counties 95 (87.2) 14 (12.8) 91 (83.5) 18 (16.5) 35 (32.1) 74 (67.9)
Data collection 0.001 0.005 0.007
 Healthcare institutions 127 (97.7) 3 (2.3) 123 (94.6) 7 (5.4) 42 (32.6) 87 (67.4)
 Korea Queer Culture Festivals (Seoul, Daegu) 19 (86.4) 3 (13.6) 17 (77.3) 5 (22.7) 12 (54.5) 10 (45.5)
 Online/offline transgender communities 107 (84.9) 19 (15.1) 103 (83.1) 21 (16.9) 61 (50.8) 59 (49.2)

Values are presented as number (%).

GID, gender identity disorder; KRW, Korean won.

1 Not all study participants answered each question; Number of respondents diagnosed with GID who provided: educational level (n=233), annual household income and employment status (n=232), and residential area (n=234).

2 p-value of the chi-square test comparing the prevalence of being or not being diagnosed with GID across different sociodemographic groups.

3 Not all study participants answered each question; Number of respondents who received hormone therapy who provided: educational level (n=225), annual household income (n=223), employment status (n=225), and residential area (n=226).

4 p-value of the chi-square test comparing the prevalence of receiving or not receiving hormone therapy across different sociodemographic groups.

5 Not all study participants answered each question; Number of respondents who had at least one sex reassignment surgery who provided: educational level and annual household income (n=108), employment status (n=106), and residential area (n=108).

6 p-value of the chi-square test comparing the prevalence of having or not having sex reassignment surgery across different sociodemographic groups.

7 Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

8 Not all study participants provided this information; Number of non-responses: educational level (n=24), annual household income (n=26), employment status (n=25), and residential area (n=23).

9 Included Sejong metropolitan autonomous city.

Table 4.
Experience of diagnosis with GID and reasons for not pursuing GID diagnosis
GID diagnosis Distribution (n=278) Gender identity spectrum1
Transfeminine (n=173) Transmasculine (n=105)
Yes 253 (91.0) 164 (94.8) 89 (84.8)
No 25 (9.0) 9 (5.2) 16 (15.2)
Reason for not pursing GID diagnosis (n=25)2
 I was having financial difficulties 12 (48.0) 4 (44.4) 8 (50.0)
 I was debating whether I should see a doctor for a diagnosis 11 (44.0) 2 (22.2) 9 (56.3)
 I am currently not in need of a diagnosis of gender identity disorder 11 (44.0) 3 (33.0) 8 (50.0)
 I was worried about possible discrimination associated with a psychiatric diagnosis on my medical history 9 (36.0) 3 (33.0) 6 (37.5)
 I could not find a psychiatrist who would provide an adequate diagnosis 7 (28.0) 2 (22.2) 5 (31.3)
 I am currently seeing a counsellor/psychiatrist for counselling services 7 (28.0) 3 (33.3) 4 (25.0)
 I was concerned with the stigma associated with having a mental disorder 4 (16.0) 3 (33.3) 1 (6.3)
 My family and/or friends advised against it 1 (4.0) 0 (0.0) 1 (6.3)
 I was refused a diagnosis of gender identity disorder 0 (0.0) 0 (0.0) 0 (0.0)
 Other reasons 3 (12.0) 1 (11.1) 2 (12.5)

Values are presented as number (%).

GID, gender identity disorder.

1 Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

2 Respondents could select multiple choices.

Table 5.
Experience of hormone therapy and reasons for not currently receiving hormone therapy
Currently receiving hormone therapy Distribution (n=276) Gender identity spectrum1
Transfeminine (n=171) Transmasculine (n=105)
Yes 225 (81.5) 150 (87.7) 75 (71.4)
No 51 (18.5) 21 (12.3) 30 (28.6)
Reason for not currently receiving hormone therapy (n=51)2
 I was having financial difficulties 28 (54.9) 10 (47.6) 18 (60.0)
 I believed it would raise difficulties in my economic activities such as finding employment and working 24 (47.1) 8 (38.1) 16 (53.3)
 It raised health issues 23 (45.1) 9 (42.9) 14 (46.7)
 I did not have a medical certificate from a psychiatrist 17 (33.3) 4 (19.0) 13 (43.3)
 I was debating whether I should receive hormone therapy 15 (29.4) 2 (9.5) 13 (43.3)
 I was worried about potential stigma from other people around me 13 (25.5) 5 (23.8) 8 (26.7)
 My family and/or friends advised against it 8 (15.7) 1 (4.8) 7 (23.3)
 I did not have access to healthcare facilities that provided hormone therapy 8 (15.7) 3 (14.3) 5 (16.7)
 I did not think hormone therapy was necessary 7 (13.7) 3 (14.3) 4 (13.3)
 I was preparing for a sex reassignment surgery 4 (7.8) 3 (14.3) 1(3.3)
 The sex reassignment surgery has successfully altered my physical appearance 3 (5.9) 2 (9.5) 1 (3.3)
 I believed it would reduce my reproductive capacity 2 (3.9) 1 (4.8) 1 (3.3)
 Other reasons 10 (19.6) 3 (14.3) 7 (23.3)

Values are presented as number (%).

1 Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

2 Respondents could select multiple choices.

Table 6.
Experience of, routes to, and reasons for purchasing hormone medications without a prescription
Ever purchased hormone medications without a prescription Distribution (n=243) Gender identity spectrum1
Transfeminine (n=160) Transmasculine (n=83)
No 182 (74.9) 109 (68.1) 73 (88.0)
Yes 61 (25.1) 51 (31.9) 10 (12.0)
Ever purchased hormone medications without a prescription (yes; n=61)2
 Over-the-counter medicines 28 (45.9) 26 (51.0) 2 (20.0)
 Online foreign vendors/suppliers 19 (31.1) 18 (35.3) 1 (10.0)
 Acquaintances/friends 15 (24.6) 8 (15.7) 7 (70.0)
 Online domestic vendors/suppliers 10 (16.4) 9 (17.6) 1 (10.0)
 Offline vendors/suppliers 5 (8.2) 4 (7.8) 1 (10.0)
Reason for ever purchasing hormone medications without a prescription (n=61)2
 I did not have a diagnosis from a psychiatrist 34 (55.7) 28 (54.9) 6 (60.0)
 I did not know healthcare facilities where I could acquire prescription for hormone medications 15 (24.6) 11 (21.6) 4 (40.0)
 I did not want to have a record of medical treatment on my medical history 10 (16.4) 8 (15.7) 2 (20.0)
 Purchase hormone medications without a prescription was a cheaper choice 10 (16.4) 6 (11.8) 4 (40.0)
 I did not want to go to a hospital 10 (16.4) 6 (11.8) 4 (40.0)
 Other reasons 17 (27.9) 14 (27.5) 3 (30.0)

Values are presented as number (%).

1 Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

2 Respondents could select multiple choices.

Table 7.
Experience of sex reassignment surgery and reasons for not having sex reassignment surgery
Sex reassignment surgery Distribution (n=271) Gender identity spectrum1
Transfeminine (n=168) Transmasculine (n=103)
Yes 115 (42.4) 57 (33.9) 58 (56.3)
No 156 (57.6) 111 (66.1) 45 (43.7)
Reason for not having sex reassignment surgery (n=156)2
 The surgery was too costly 122 (78.2) 85 (76.6) 37 (82.2)
 I wish to receive the surgery eventually, but I am not ready for it right now 100 (64.1) 68 (61.3) 32 (71.1)
 I believed it would raise difficulties in my economic activities such as finding employment and working 57 (36.5) 37 (33.3) 20 (44.4)
 My family and/or friends advised against it 39 (25.0) 30 (27.0) 9 (20.0)
 The dangers of the surgery were too high 36 (23.1) 27 (24.3) 9 (20.0)
 I was worried about potential stigma from other people around me 32 (20.5) 22 (19.8) 10 (22.2)
 I have not met the medical requirements for the surgery 27 (17.3) 19 (17.1) 8 (17.8)
 The surgery would not guarantee satisfactory sexual function 19 (12.2) 9 (8.1) 10 (22.2)
 I did not have access to healthcare facilities that provided sex reassignment surgery 11 (7.1) 6 (5.4) 5 (11.1)
 I did not think sex reassignment surgery was necessary 10 (6.4) 5 (4.5) 5 (11.1)
 It raised issues regarding family planning and reproduction such as pregnancy and childbirth 7 (4.5) 3 (2.7) 4 (8.9)
 I was refused a sex reassignment surgery 1 (0.6) 1 (0.9) 0 (0.0)
 Other reasons 13 (8.3) 10 (9.0) 3 (6.7)

Values are presented as number (%).

1 Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

2 Respondents could select multiple choices.

  • 1. American Psychological Association. Answers to your questions: about transgender people, gender identity, and gender expression; 2011 [cited 2018 Feb 9]. Available from: http://www.apa.org/topics/lgbt/transgender.pdf.Article
  • 2. Coleman E, Bockting W, Botzer M, Cohen-Kettenis P, DeCuypere G, Feldman J, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend 2012;13:165-232.Article
  • 3. James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The report of the 2015 U.S. transgender survey; 2016 [cited 2018 May 24]. Available from: https://www.transequality.org/sites/default/files/docs/USTS-Full-Report-FINAL.PDF.
  • 4. Reisner SL, Poteat T, Keatley J, Cabral M, Mothopeng T, Dunham E, et al. Global health burden and needs of transgender populations: a review. Lancet 2016;388:412-436.ArticlePubMedPMC
  • 5. Meerwijk EL, Sevelius JM. Transgender population size in the United States: a meta-regression of population-based probability samples. Am J Public Health 2017;107:e1-e8.Article
  • 6. Korean Statistical Information Service. KOSIS 100 indicators. [cited 2018 Feb 9]. Available from: http://kosis.kr/conts/nsportalStats/nsportalStats_0102Body.jsp?menuId=10&NUM=1014 (Korean).
  • 7. Yi H, Lee H, Yoon JW, Park J, Kim S-S. Transgender people’s access to health care in Korea. Health Soc Welf Rev 2015;35:64-94 (Korean).Article
  • 8. Murad MH, Elamin MB, Garcia MZ, Mullan RJ, Murad A, Erwin PJ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf) 2010;72:214-231.ArticlePubMed
  • 9. Weyers S, Elaut E, De Sutter P, Gerris J, T’sjoen G, Heylens G, et al. Long-term assessment of the physical, mental, and sexual health among transsexual women. J Sex Med 2009;6:752-760.ArticlePubMed
  • 10. Wilson EC, Chen YH, Arayasirikul S, Wenzel C, Raymond HF. Connecting the dots: examining transgender women’s utilization of transition-related medical care and associations with mental health, substance use, and HIV. J Urban Health 2015;92:182-192.ArticlePubMed
  • 11. Son I, Lee H, Park J, Kim SS. Social stigma and medical marginalization in healthcare service among transgender people in South Korea. Korean J Sociol 2017;51:155-189 (Korean).Article
  • 12. Choi SK. The sex correction of transsexuals and its standards: focusing on ‘the Supreme Court 2011.9.2. 2009스 117’ case. Korean J Fam Law 2013;27:373-412 (Korean).
  • 13. Hong SP, Lee SH. A legal appraisal of the medical intervention in the gender recognition of transgender under the international human rights and the Korean law, with focus on the recent decision of the Seoul Western District Court. Korean J Int Comp Law 2013;58:131-160 (Korean).
  • 14. Park H. Transgender people and their obligation to serve in the military in South Korea. The 8th LGBTI Human Rights Forum. 2016 Mar 4-6. Seoul, Korea: Seoul: The 8th LGBTI Human Rights Forum Planning Group; 2016. 131-141 (Korean, author’s translation).
  • 15. Kim YJ. A study of fundamental rights that the person owns transsexualism is guaranteed. [dissertation]. Seoul: Korea University; 2012. (Korean).
  • 16. Lee H, Park J, Kim SS. LGBTQI health research in South Korea: a systematic review. Health Soc Sci 2014;36:43-76 (Korean).
  • 17. Reisner SL, Conron KJ, Tardiff LA, Jarvi S, Gordon AR, Austin SB. Monitoring the health of transgender and other gender minority populations: validity of natal sex and gender identity survey items in a US national cohort of young adults. BMC Public Health 2014;14:1224.ArticlePubMedPMCPDF
  • 18. Chang SY, Kim JH, Kim HK, Na YJ, Jung HH, Ryu MH, et al. A survey on discrimination based on sexual orientation and gender identity in South Korea; 2014 [cited 2018 May 24]. Available from: https://library.humanrights.go.kr/search/media/img/CAT000000038573?metsno=000000000936&fileid=M000000000936_FILE000001 (Korean).
  • 19. Dewey JM, Gesbeck MM. (Dys) Functional diagnosing mental health diagnosis, medicalization, and the making of transgender patients. Humanit Soc 2017;41:37-72.Article
  • 20. Dowshen N, Nguyen GT, Gilbert K, Feiler A, Margo KL, Stroumsa D. Improving transgender health education for future doctors. Am J Public Health 2014;104:e5-e6.Article
  • 21. Safer JD, Pearce EN. A simple curriculum content change increased medical student comfort with transgender medicine. Endocr Pract 2013;19:633-637.ArticlePubMedPDF
  • 22. Lombardi E. Enhancing transgender health care. Am J Public Health 2001;91:869-872.ArticlePubMedPMC
  • 23. Rotondi NK, Bauer GR, Scanlon K, Kaay M, Travers R, Travers A. Nonprescribed hormone use and self-performed surgeries: “do-it-yourself” transitions in transgender communities in Ontario, Canada. Am J Public Health 2013;103:1830-1836.ArticlePubMedPMC
Appendix 1.
Cost1 of gender identity disorder (GID) diagnosis and sex reassignment surgery
Cost of GID diagnosis (n=251) Distribution Gender identity spectrum2
Transfeminine (n=162)
 Transmasculine(n=89)
n (%) n (%) n (%)
<25 42 (16.7) 26 (16.0) 16 (18.0)
25-49 170 (67.7) 110 (67.9) 60 (67.4)
50-74 22 (8.8) 11 (6.8) 11 (12.4)
>74 17 (6.8) 15 (9.3) 2 (2.2)
Sex reassignment surgery (n=115) Distribution
 Transfeminine (n=57)
 Transmasculine(n=58)
n n Average cost (SD) n Average cost (SD)
Breast/chest 71 17 532.4 (443.3) 54 368.5 (146.4)
Orchiectomy, hysterectomy/salpingo-oophorectomy 63 21 297.1 (523.8) 42 397.6 (290.1)
Genital reconstruction 34 27 1,514.8 (657.3) 7 2,057.1 (1,135.6)
Face 30 27 1,159.6 (1,048.5) 3 366.7 (57.7)
Voice 9 9 655.6 (545.7) - -
Others 9 7 132.9 (118.1) 2 100 (0.0)

1 10,000 Korean won.

2 Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

Appendix 2.
Distribution of study population and experiences of delaying or avoiding hospital visits and being denied healthcare services among transgender adults in Korea within the past 12 months
Distribution (n=262) Delaying or avoiding hospital visits (n=112)
 Being denied healthcare services (n=14)
p-value1 p-value2
Gender identity spectrum3 0.02 0.17
 Transfeminine 160 (61.1) 59 (36.9) 11 (6.9)
 Transmasculine 102 (38.9) 53 (52.0) 3 (2.9)
Age (yr) 0.04 0.91
 19-29 209 (79.8) 96 (45.9) 11 (5.3)
 30-50 53 (20.2) 16 (30.2) 3 (5.7)
Sexual orientation 0.27 0.003
 Heterosexual 123 (46.9) 52 (42.3) 4 (3.3)
 Homosexual 26 (9.9) 9 (34.6) 2 (7.7)
 Bisexual 90 (34.4) 37 (41.1) 3 (3.3)
 Asexual 23 (8.8) 14 (60.9) 5 (21.7)
Educational level4 0.24 0.62
 ≤High school graduate 57 (22.5) 25 (43.9) 2 (3.5)
 College graduate 39 (15.4) 12 (30.8) 2 (5.1)
 University graduate 144 (56.9) 68 (47.2) 10 (6.9)
 ≥Graduate school graduate 13 (5.1) 4 (30.8) 0 (0.0)
Household income4 (104 KRW) 0.38 0.67
 <1,000 69 (27.5) 30 (43.5) 6 (8.7)
 1,000-1,999 52 (20.7) 28 (53.8) 3 (5.8)
 2,000-2,999 45 (17.9) 16 (35.6) 1 (2.2)
 3,000-4,999 43 (17.1) 16 (37.2) 2 (4.7)
 ≥5,000 42 (16.7) 17 (40.5) 2 (4.8)
Employment status4 0.67 0.93
 Unemployed 117 (46.4) 53 (45.3) 7 (6.0)
 Non-precarious employment 45 (17.9) 21 (46.7) 2 (4.4)
 Precarious employment 78 (31.0) 29 (37.2) 3 (3.8)
 Self-employed 11 (4.4) 5 (45.5) 1 (9.1)
 Unpaid family worker 1 (0.4) 0 (0.0) 0 (0.0)
Residential area4 0.43 0.22
 Seoul metropolitan city 104 (40.9) 49 (47.1) 4 (3.8)
 Other metropolitan cities5 42 (16.5) 15 (35.7) 1 (2.4)
 Other cities and counties 108 (42.5) 45 (41.7) 9 (8.3)
Data collection 0.07 0.15
 Healthcare institutions 127 (48.5) 48 (37.8) 7 (5.5)
 The Korean Queer Culture Festivals (Seoul, Daegu) 22 (8.4) 14 (63.6) 3 (13.6)
 Online/offline transgender communities 113 (43.1) 50 (44.2) 4 (3.5)

Values are presented as number (%).

KRW, Korean won.

1 p-value of chi-square test comparing prevalence of delaying or avoiding hospital visits across sociodemographic groups.

2 p-value of chi-square test comparing prevalence of being denied healthcare services across sociodemographic groups.

3 Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

4 Not all study participants provided this information. Number of non-responses: educational level (n=9), household income (n=11), employment status (n=10), and residential area (n=8).

5 Included Sejong metropolitan autonomous city.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Situational Avoidance and Its Association with Mental Health Among Transgender Adults in South Korea: A Nationwide Cohort Study
      Yun-Jung Eom, Hyemin Lee, Sungsub Choo, Ranyeong Kim, Horim Yi, Rockli Kim, Seung-Sup Kim
      LGBT Health.2024; 11(2): 122.     CrossRef
    • Invisibility and Stigma: Experiences of Transgender and Gender Non-Conforming Individuals in South Korea
      Eunha Kim, Hyun Park, YeJi Cho, KyungAh Jeon, Hyunju An
      Archives of Sexual Behavior.2024; 53(1): 77.     CrossRef
    • Does discrimination prevent transgender and gender diverse people from seeking healthcare?: A nationwide cohort study in South Korea
      Ranyeong Kim, Sungsub Choo, Hyemin Lee, Yun-Jung Eom, Horim Yi, Rockli Kim, Seung-Sup Kim
      International Journal of Transgender Health.2024; 25(2): 283.     CrossRef
    • Βarriers and Gaps to Medical Care for Transgender Individuals: A TRANSCARE Scoping Review with a Focus on Greece
      Marilena Anastasaki, Agapi Angelaki, Philippos Paganis, Elena Olga Christidi, Nancy Papathanasiou, Eleni Panagiota Stoupa, Evika Karamagioli, Emmanouil Pikoulis, Christos Lionis
      Healthcare.2024; 12(6): 647.     CrossRef
    • Creating the Chinese version of the transgender attitudes and beliefs scale
      Zhanqiang Wang, Yang Liu, Hanwen Dong, Yueqian Zhang, Kebing Yang, Qingyan Yang, Xiaolan Di, Yajuan Niu
      BMC Psychology.2024;[Epub]     CrossRef
    • Barriers and Facilitators to Accessing and Providing Gender Affirming Hormone Therapy: A Scoping Review
      Lauren Porsch-Ortega, Shweta Athilat, Shivani Kochhar, Melanie McDonald
      Transgender Health.2024;[Epub]     CrossRef
    • Cross-Cultural Adaptation and Face Validation of the Chilean Version of the Operated Male to Female Sexual Function Index
      Betzabe Cueto-Galdames, Melissa Cifuentes, Francesca Vedovo, Cinara Sacomori
      International Urogynecology Journal.2024; 35(6): 1271.     CrossRef
    • Instruments used to assess gender-affirming healthcare access: A scoping review
      Seán Kearns, Philip Hardie, Donal O’Shea, Karl Neff, Joseph Adu
      PLOS ONE.2024; 19(6): e0298821.     CrossRef
    • Health of Korean sexual and gender minorities: a narrative review of quantitative studies
      Heesung So, Ssirai Kim, Sun Young Lee
      The Ewha Medical Journal.2024;[Epub]     CrossRef
    • Gender-Affirming Surgery in Low- and Middle-Income Countries: A Systematic Review
      Viraj Shah, Bashar Hassan, Rena Hassan, Malory Alexis, Myan Bhoopalam, Lorreen Agandi, Fan Liang
      Journal of Clinical Medicine.2024; 13(12): 3580.     CrossRef
    • Gender Identity Change Efforts Are Associated with Depression, Panic Disorder, and Suicide Attempts in South Korean Transgender Adults
      Hyemin Lee, Don Operario, Arjee J. Restar, Sungsub Choo, Ranyeong Kim, Yun-Jung Eom, Horim Yi, Seung-Sup Kim
      Transgender Health.2023; 8(3): 273.     CrossRef
    • Transgender-specific COVID-19-related stressors and their association with depressive symptoms among transgender adults: A nationwide cross-sectional survey in South Korea
      Hyemin Lee, Arjee J. Restar, Don Operario, Sungsub Choo, Carl G. Streed Jr, Horim Yi, Ranyeong Kim, Yun-Jung Eom, Seung-Sup Kim
      International Journal of Transgender Health.2023; 24(3): 334.     CrossRef
    • Closing the gap in education: Raising medical professionals' knowledge and attitudes in transgender health
      Gail A. Knudson, Jamie Feldman, Paula Neira, Lin Fraser
      Best Practice & Research Clinical Obstetrics & Gynaecology.2023; 89: 102339.     CrossRef
    • Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions
      Vitória Berg Cattani, Emilia Moreira Jalil, Leonardo Eksterman, Thiago Torres, Sandra Wagner Cardoso, Cristiane R. V. Castro, Laylla Monteiro, Erin Wilson, Lane Bushman, Peter Anderson, Valdilea Gonçalves Veloso, Beatriz Grinsztejn, Rita Estrela, Brenda H
      Clinical Pharmacokinetics.2023; 62(7): 1031.     CrossRef
    • Voices from a Multidisciplinary Healthcare Center: Understanding Barriers in Gender-Affirming Care—A Qualitative Exploration
      Maeghan B. Ross, Hiba Jahouh, Margriet G. Mullender, Baudewijntje P. C. Kreukels, Tim C. van de Grift
      International Journal of Environmental Research and Public Health.2023; 20(14): 6367.     CrossRef
    • An Analysis of the Demographics and Clinical Characteristics of Transgender and Intersex Populations in Korea: A Retrospective Study Using HIRA Database
      Dong-Jin Kim, Na-Hyun Hwang, Ji Yoon Lee, Seung Ha Park, Byung-Il Lee, Eul-Sik Yoon
      Journal of Korean Medical Science.2023;[Epub]     CrossRef
    • Job-Seeking Experiences of Trans Adults in South Korea
      Jimin Sung, Jaehee Yi, Min Ah Kim, Gaben Sanchez
      Journal of Homosexuality.2023; : 1.     CrossRef
    • Intersectional examination of transgender women in South Korea: a case study of the dismissal of the first transgender officer by the Ministry of National Defense
      Jungman Park, Jianwen LIU
      International Journal of Korean Humanities and Social Sciences.2023; 9: 47.     CrossRef
    • Does Discrimination Affect Whether Transgender People Avoid or Delay Healthcare?: A Nationwide Cross-sectional Survey in South Korea
      Hyemin Lee, Don Operario, Horim Yi, Sungsub Choo, Ji-Hwan Kim, Seung-Sup Kim
      Journal of Immigrant and Minority Health.2022; 24(1): 170.     CrossRef
    • Restriction of Access to Healthcare and Discrimination of Individuals of Sexual and Gender Minority: An Analysis of Judgments of the European Court of Human Rights from an Ethical Perspective
      Tobias Skuban, Marcin Orzechowski, Florian Steger
      International Journal of Environmental Research and Public Health.2022; 19(5): 2650.     CrossRef
    • Study protocol: navigating access to gender care in Ireland—a mixed-method study on the experiences of transgender and non-binary youth
      Seán Kearns, Catherine Houghton, Donal O’Shea, Karl Neff
      BMJ Open.2022; 12(3): e052030.     CrossRef
    • Korean healthcare providers’ attitude, knowledge, and behaviors regarding sexual orientation and gender identity: a cross-sectional survey
      YunHui An, ChaeWeon Chung
      Korean Journal of Women Health Nursing.2022; 28(1): 65.     CrossRef
    • Discrimination keeps transgender people awake at night: A nationwide cross-sectional survey of 583 transgender adults in South Korea
      Yun-Jung Eom, Hyemin Lee, Ranyeong Kim, Sungsub Choo, Horim Yi, Seung-Sup Kim
      Sleep Health.2022; 8(6): 580.     CrossRef
    • Heterogeneity in the Desire to Undergo Various Gender-Affirming Medical Interventions Among Transgender People in Hong Kong: Findings from a Community-Driven Survey and Implications for the Legal Gender Recognition Debate
      Yiu Tung Suen, Randolph C. H. Chan, Eliz Miu Yin Wong
      Archives of Sexual Behavior.2022; 51(7): 3613.     CrossRef
    • Fertility Preservation and Reproductive Potential in Transgender and Gender Fluid Population
      Ji Young Choi, Tae Jin Kim
      Biomedicines.2022; 10(9): 2279.     CrossRef
    • A Review of Gender-Affirming Hormone Therapy for Transgender and Gender Diverse Adults in South Korea
      Jeong-Won OH, Yeoul Yun, Eun Sil Lee
      Journal of Menopausal Medicine.2022; 28(3): 92.     CrossRef
    • Unpacking the Roles of Religion and Partisanship on Support for Same-Sex Marriage: Evidence from South Korea
      Timothy S Rich, Andi Dahmer, Isabel Eliassen
      Journal of Asian and African Studies.2021; 56(2): 364.     CrossRef
    • Attitudes Toward Transgender People Among Medical Students in South Korea
      Sa Ra Lee, Min-A Kim, Mun Nyeong Choi, Suyeon Park, Jaehyun Cho, Chulmin Lee, Eun Sil Lee
      Sexual Medicine.2021; 9(1): 100278.     CrossRef
    • Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial
      Supanat Burinkul, Krasean Panyakhamlerd, Ammarin Suwan, Punkavee Tuntiviriyapun, Sorawit Wainipitapong
      The Journal of Sexual Medicine.2021; 18(7): 1299.     CrossRef
    • Transgender Adults' Public Bathroom-Related Stressors and Their Association with Depressive Symptoms: A Nationwide Cross-Sectional Study in South Korea
      Hyemin Lee, Horim Yi, G. Nic Rider, Don Operario, Sungsub Choo, Ranyeong Kim, Yun-Jung Eom, Seung-Sup Kim
      LGBT Health.2021; 8(7): 486.     CrossRef
    • Experiences of transgender and non-binary youth accessing gender-affirming care: A systematic review and meta-ethnography
      Seán Kearns, Thilo Kroll, Donal O‘Shea, Karl Neff, Michelle Torok
      PLOS ONE.2021; 16(9): e0257194.     CrossRef
    • Fertility Preservation for Transgender Individuals
      Alessandra J. Ainsworth, Megan Allyse, Zaraq Khan
      Mayo Clinic Proceedings.2020; 95(4): 784.     CrossRef
    • Health Disparities Among Transgender Adults in South Korea
      Hyemin Lee, Don Operario, Jacob J. van den Berg, Horim Yi, Sungsub Choo, Seung-Sup Kim
      Asia Pacific Journal of Public Health.2020; 32(2-3): 103.     CrossRef
    • Internalized transphobia and mental health among transgender adults: A nationwide cross-sectional survey in South Korea
      Hyemin Lee, Kevin K. Tomita, Janice M. Habarth, Don Operario, Horim Yi, Sungsub Choo, Seung-Sup Kim
      International Journal of Transgender Health.2020; 21(2): 182.     CrossRef
    • Gender affirmative care of transgender people: a single center's experience in Korea
      Hyun Hye Lim, Yun Ha Jang, Gyu Yeon Choi, Jeong Jae Lee, Eun Sil Lee
      Obstetrics & Gynecology Science.2019; 62(1): 46.     CrossRef
    • Effects of Estradiol Therapy on Resting-State Functional Connectivity of Transgender Women After Gender-Affirming Related Gonadectomy
      Maiko A. Schneider, Poli M. Spritzer, Luciano Minuzzi, Benicio N. Frey, Sabrina K. Syan, Tayane M. Fighera, Karine Schwarz, Ângelo B. Costa, Dhiordan C. da Silva, Cláudia C. G. Garcia, Anna M. V. Fontanari, André G. Real, Maurício Anes, Juliana U. Castan,
      Frontiers in Neuroscience.2019;[Epub]     CrossRef
    • Health Needs of Trans and Gender Diverse Adults in Australia: A Qualitative Analysis of a National Community Survey
      Sav Zwickl, Alex Wong, Ingrid Bretherton, Max Rainier, Daria Chetcuti, Jeffrey D. Zajac, Ada S. Cheung
      International Journal of Environmental Research and Public Health.2019; 16(24): 5088.     CrossRef

    Experiences of and barriers to transition-related healthcare among Korean transgender adults: focus on gender identity disorder diagnosis, hormone therapy, and sex reassignment surgery
    Experiences of and barriers to transition-related healthcare among Korean transgender adults: focus on gender identity disorder diagnosis, hormone therapy, and sex reassignment surgery
    Current gender identity Legal sex at birth
    Male Female
    Man Cisgender2 Transmasculine
    Woman Transfeminine Cisgender2
    Do not identify as man or woman Transfeminine Transmasculine
    All respondents (n=278) Gender identity spectrum1
    		 p-value2
    Transfeminine (n=173) Transmasculine (n=105)
    Age (yr) <0.001
     19-29 218 (78.4) 124 (56.9) 94 (43.1)
     30-50 60 (21.6) 49 (81.7) 11 (18.3)
    Sexual orientation 0.001
     Heterosexual 129 (46.4) 65 (50.4) 64 (49.6)
     Homosexual 29 (10.4) 24 (82.8) 5 (17.2)
     Bisexual 96 (34.5) 66 (68.8) 30 (31.3)
     Asexual 24 (8.6) 18 (75.0) 6 (25.0)
    Educational level3 0.87
     ≤High school graduate 57 (22.4) 34 (59.7) 23 (40.4)
     College graduate 39 (15.4) 25 (64.1) 14 (35.9)
     University graduate 145 (57.1) 86 (59.3) 59 (40.7)
     ≥Graduate school graduate 13 (5.1) 9 (69.2) 4 (30.8)
    Annual household income (104 KRW) 0.24
     <1,000 69 (27.4) 48 (69.6) 21 (30.4)
     1,000-1,999 53 (21.0) 30 (56.6) 23 (43.4)
     2,000-2,999 45 (17.9) 30 (66.7) 15 (33.3)
     3,000-4,999 43 (17.1) 25 (58.1) 18 (41.9)
     ≥5,000 42 (16.7) 21 (50.0) 21 (50.0)
    Employment status3 0.42
     Unemployed 118 (46.6) 69 (58.5) 49 (41.5)
     Non-precarious employment 45 (17.8) 28 (62.2) 17 (37.8)
     Precarious employment 78 (30.8) 48 (61.5) 30 (38.5)
     Self-employed 11 (4.3) 9 (81.8) 2 (18.2)
     Unpaid family worker 1 (0.4) 0 (0.0) 1 (100.0)
    Residential area3 0.95
     Seoul metropolitan city 104 (40.8) 62 (59.6) 42 (40.4)
     Other metropolitan cities4 42 (16.5) 26 (61.9) 16 (38.1)
     Other cities and counties 109 (42.7) 67 (61.5) 42 (38.5)
    Data collection 0.33
     Healthcare institutions 130 (46.8) 79 (60.8) 51 (39.2)
     Korea Queer Culture Festivals (Seoul, Daegu) 22 (7.9) 11 (50.0) 11 (50.0)
     Online/offline transgender communities 126 (45.3) 83 (65.9) 43 (34.1)
    Transition-related healthcare
    GID diagnosis (n=278)
    		 Hormone therapy (n=276)
    		 Sex reassignment surgery (n=271)
    Respondents who were diagnosed with GID (n=253)1 Respondents who were not diagnosed with GID (n=25) p-value2 Respondents who received hormone therapy (n=243)3 Respondents who did not receive hormone therapy (n=33) p-value4 Respondents who underwent sex reassignment surgery (n=115)5 Respondents who did not undergo sex reassignment surgery (n=156) p-value6
    Gender identity spectrum7 0.005 <0.001 <0.001
     Transfeminine 164 (94.8) 9 (5.2) 160 (93.6) 11 (6.4) 57 (33.9) 111 (66.1)
     Transmasculine 89 (84.8) 16 (15.2) 83 (79.0) 22 (21.0) 58 (56.3) 45 (43.7)
    Age (yr) 0.02 0.006 0.71
     19-29 194 (89.0) 24 (11.0) 185 (85.3) 32 (14.7) 90 (41.9) 125 (58.1)
     30-50 59 (98.3) 1 (1.7) 58 (98.3) 1 (1.7) 25 (44.6) 31 (55.4)
    Sexual orientation 0.26 0.70 0.001
     Heterosexual 120 (93.0) 9 (7.0) 116 (89.9) 13 (10.1) 68 (54.4) 57 (45.6)
     Homosexual 24 (82.8) 5 (17.2) 23 (82.1) 5 (17.9) 11 (39.3) 17 (60.7)
     Bisexual 86 (89.6) 10 (10.4) 83 (87.4) 12 (12.6) 26 (27.7) 68 (72.3)
     Asexual 23 (95.8) 1 (4.2) 21 (87.5) 3 (12.5) 10 (41.7) 14 (58.3)
    Educational level8 0.73 0.88 0.28
     ≤High school graduate 53 (93.0) 4 (7.0) 52 (91.2) 5 (8.8) 19 (33.3) 38 (66.7)
     College graduate 35 (89.7) 4 (10.3) 34 (87.2) 5 (12.8) 17 (43.6) 22 (56.4)
     University graduate 134 (92.4) 11 (7.6) 128 (88.3) 17 (11.7) 68 (46.9) 77 (53.1)
     ≥Graduate school graduate 11 (84.6) 2 (15.4) 11 (84.6) 2 (15.4) 4 (30.8) 9 (69.2)
    Annual household income (104 KRW)8 0.38 0.21 0.10
     <1,000 61 (88.4) 8 (11.6) 58 (84.1) 11 (15.9) 26 (37.7) 43 (62.3)
     1,000-1,999 51 (96.2) 2 (3.8) 51 (96.2) 2 (3.8) 29 (54.7) 24 (45.3)
     2,000-2,999 42 (93.3) 3 (6.7) 41 (91.1) 4 (8.9) 17 (37.8) 28 (62.2)
     3,000-4,999 41 (95.3) 2 (4.7) 38 (88.4) 5 (11.6) 14 (32.6) 29 (67.4)
     ≥5,000 37 (88.1) 5 (11.9) 35 (83.3) 7 (16.7) 22 (52.4) 20 (47.6)
    Employment status8 0.006 0.002 0.68
     Unemployed 105 (89.0) 13 (11.0) 98 (83.1) 20 (16.9) 54 (45.8) 64 (54.2)
     Non-precarious employment 42 (93.3) 3 (6.7) 42 (93.3) 3 (6.7) 19 (42.2) 26 (57.8)
     Precarious employment 74 (94.9) 4 (5.1) 74 (94.9) 4 (5.1) 29 (37.2) 49 (62.8)
     Self-employed 11 (100.0) 0 (0.0) 11 (100.0) 0 (0.0) 4 (36.4) 7 (63.6)
     Unpaid family worker 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
    Residential area8 0.07 0.08 0.02
     Seoul metropolitan city 99 (95.2) 5 (4.8) 96 (92.3) 8 (7.7) 52 (50.0) 52 (50.0)
     Other metropolitan cities9 40 (95.2) 2 (4.8) 39 (92.9) 3 (7.1) 21 (50.0) 21 (50.0)
     Other cities and counties 95 (87.2) 14 (12.8) 91 (83.5) 18 (16.5) 35 (32.1) 74 (67.9)
    Data collection 0.001 0.005 0.007
     Healthcare institutions 127 (97.7) 3 (2.3) 123 (94.6) 7 (5.4) 42 (32.6) 87 (67.4)
     Korea Queer Culture Festivals (Seoul, Daegu) 19 (86.4) 3 (13.6) 17 (77.3) 5 (22.7) 12 (54.5) 10 (45.5)
     Online/offline transgender communities 107 (84.9) 19 (15.1) 103 (83.1) 21 (16.9) 61 (50.8) 59 (49.2)
    GID diagnosis Distribution (n=278) Gender identity spectrum1
    Transfeminine (n=173) Transmasculine (n=105)
    Yes 253 (91.0) 164 (94.8) 89 (84.8)
    No 25 (9.0) 9 (5.2) 16 (15.2)
    Reason for not pursing GID diagnosis (n=25)2
     I was having financial difficulties 12 (48.0) 4 (44.4) 8 (50.0)
     I was debating whether I should see a doctor for a diagnosis 11 (44.0) 2 (22.2) 9 (56.3)
     I am currently not in need of a diagnosis of gender identity disorder 11 (44.0) 3 (33.0) 8 (50.0)
     I was worried about possible discrimination associated with a psychiatric diagnosis on my medical history 9 (36.0) 3 (33.0) 6 (37.5)
     I could not find a psychiatrist who would provide an adequate diagnosis 7 (28.0) 2 (22.2) 5 (31.3)
     I am currently seeing a counsellor/psychiatrist for counselling services 7 (28.0) 3 (33.3) 4 (25.0)
     I was concerned with the stigma associated with having a mental disorder 4 (16.0) 3 (33.3) 1 (6.3)
     My family and/or friends advised against it 1 (4.0) 0 (0.0) 1 (6.3)
     I was refused a diagnosis of gender identity disorder 0 (0.0) 0 (0.0) 0 (0.0)
     Other reasons 3 (12.0) 1 (11.1) 2 (12.5)
    Currently receiving hormone therapy Distribution (n=276) Gender identity spectrum1
    Transfeminine (n=171) Transmasculine (n=105)
    Yes 225 (81.5) 150 (87.7) 75 (71.4)
    No 51 (18.5) 21 (12.3) 30 (28.6)
    Reason for not currently receiving hormone therapy (n=51)2
     I was having financial difficulties 28 (54.9) 10 (47.6) 18 (60.0)
     I believed it would raise difficulties in my economic activities such as finding employment and working 24 (47.1) 8 (38.1) 16 (53.3)
     It raised health issues 23 (45.1) 9 (42.9) 14 (46.7)
     I did not have a medical certificate from a psychiatrist 17 (33.3) 4 (19.0) 13 (43.3)
     I was debating whether I should receive hormone therapy 15 (29.4) 2 (9.5) 13 (43.3)
     I was worried about potential stigma from other people around me 13 (25.5) 5 (23.8) 8 (26.7)
     My family and/or friends advised against it 8 (15.7) 1 (4.8) 7 (23.3)
     I did not have access to healthcare facilities that provided hormone therapy 8 (15.7) 3 (14.3) 5 (16.7)
     I did not think hormone therapy was necessary 7 (13.7) 3 (14.3) 4 (13.3)
     I was preparing for a sex reassignment surgery 4 (7.8) 3 (14.3) 1(3.3)
     The sex reassignment surgery has successfully altered my physical appearance 3 (5.9) 2 (9.5) 1 (3.3)
     I believed it would reduce my reproductive capacity 2 (3.9) 1 (4.8) 1 (3.3)
     Other reasons 10 (19.6) 3 (14.3) 7 (23.3)
    Ever purchased hormone medications without a prescription Distribution (n=243) Gender identity spectrum1
    Transfeminine (n=160) Transmasculine (n=83)
    No 182 (74.9) 109 (68.1) 73 (88.0)
    Yes 61 (25.1) 51 (31.9) 10 (12.0)
    Ever purchased hormone medications without a prescription (yes; n=61)2
     Over-the-counter medicines 28 (45.9) 26 (51.0) 2 (20.0)
     Online foreign vendors/suppliers 19 (31.1) 18 (35.3) 1 (10.0)
     Acquaintances/friends 15 (24.6) 8 (15.7) 7 (70.0)
     Online domestic vendors/suppliers 10 (16.4) 9 (17.6) 1 (10.0)
     Offline vendors/suppliers 5 (8.2) 4 (7.8) 1 (10.0)
    Reason for ever purchasing hormone medications without a prescription (n=61)2
     I did not have a diagnosis from a psychiatrist 34 (55.7) 28 (54.9) 6 (60.0)
     I did not know healthcare facilities where I could acquire prescription for hormone medications 15 (24.6) 11 (21.6) 4 (40.0)
     I did not want to have a record of medical treatment on my medical history 10 (16.4) 8 (15.7) 2 (20.0)
     Purchase hormone medications without a prescription was a cheaper choice 10 (16.4) 6 (11.8) 4 (40.0)
     I did not want to go to a hospital 10 (16.4) 6 (11.8) 4 (40.0)
     Other reasons 17 (27.9) 14 (27.5) 3 (30.0)
    Sex reassignment surgery Distribution (n=271) Gender identity spectrum1
    Transfeminine (n=168) Transmasculine (n=103)
    Yes 115 (42.4) 57 (33.9) 58 (56.3)
    No 156 (57.6) 111 (66.1) 45 (43.7)
    Reason for not having sex reassignment surgery (n=156)2
     The surgery was too costly 122 (78.2) 85 (76.6) 37 (82.2)
     I wish to receive the surgery eventually, but I am not ready for it right now 100 (64.1) 68 (61.3) 32 (71.1)
     I believed it would raise difficulties in my economic activities such as finding employment and working 57 (36.5) 37 (33.3) 20 (44.4)
     My family and/or friends advised against it 39 (25.0) 30 (27.0) 9 (20.0)
     The dangers of the surgery were too high 36 (23.1) 27 (24.3) 9 (20.0)
     I was worried about potential stigma from other people around me 32 (20.5) 22 (19.8) 10 (22.2)
     I have not met the medical requirements for the surgery 27 (17.3) 19 (17.1) 8 (17.8)
     The surgery would not guarantee satisfactory sexual function 19 (12.2) 9 (8.1) 10 (22.2)
     I did not have access to healthcare facilities that provided sex reassignment surgery 11 (7.1) 6 (5.4) 5 (11.1)
     I did not think sex reassignment surgery was necessary 10 (6.4) 5 (4.5) 5 (11.1)
     It raised issues regarding family planning and reproduction such as pregnancy and childbirth 7 (4.5) 3 (2.7) 4 (8.9)
     I was refused a sex reassignment surgery 1 (0.6) 1 (0.9) 0 (0.0)
     Other reasons 13 (8.3) 10 (9.0) 3 (6.7)
    Cost of GID diagnosis (n=251) Distribution Gender identity spectrum2
    		Transfeminine (n=162)
    		 Transmasculine(n=89)
    n (%) n (%) n (%)
    <25 42 (16.7) 26 (16.0) 16 (18.0)
    25-49 170 (67.7) 110 (67.9) 60 (67.4)
    50-74 22 (8.8) 11 (6.8) 11 (12.4)
    >74 17 (6.8) 15 (9.3) 2 (2.2)
    Sex reassignment surgery (n=115) Distribution
    		 Transfeminine (n=57)
    		 Transmasculine(n=58)
    n n Average cost (SD) n Average cost (SD)
    Breast/chest 71 17 532.4 (443.3) 54 368.5 (146.4)
    Orchiectomy, hysterectomy/salpingo-oophorectomy 63 21 297.1 (523.8) 42 397.6 (290.1)
    Genital reconstruction 34 27 1,514.8 (657.3) 7 2,057.1 (1,135.6)
    Face 30 27 1,159.6 (1,048.5) 3 366.7 (57.7)
    Voice 9 9 655.6 (545.7) - -
    Others 9 7 132.9 (118.1) 2 100 (0.0)
    Distribution (n=262) Delaying or avoiding hospital visits (n=112)
    		 Being denied healthcare services (n=14)
    p-value1 p-value2
    Gender identity spectrum3 0.02 0.17
     Transfeminine 160 (61.1) 59 (36.9) 11 (6.9)
     Transmasculine 102 (38.9) 53 (52.0) 3 (2.9)
    Age (yr) 0.04 0.91
     19-29 209 (79.8) 96 (45.9) 11 (5.3)
     30-50 53 (20.2) 16 (30.2) 3 (5.7)
    Sexual orientation 0.27 0.003
     Heterosexual 123 (46.9) 52 (42.3) 4 (3.3)
     Homosexual 26 (9.9) 9 (34.6) 2 (7.7)
     Bisexual 90 (34.4) 37 (41.1) 3 (3.3)
     Asexual 23 (8.8) 14 (60.9) 5 (21.7)
    Educational level4 0.24 0.62
     ≤High school graduate 57 (22.5) 25 (43.9) 2 (3.5)
     College graduate 39 (15.4) 12 (30.8) 2 (5.1)
     University graduate 144 (56.9) 68 (47.2) 10 (6.9)
     ≥Graduate school graduate 13 (5.1) 4 (30.8) 0 (0.0)
    Household income4 (104 KRW) 0.38 0.67
     <1,000 69 (27.5) 30 (43.5) 6 (8.7)
     1,000-1,999 52 (20.7) 28 (53.8) 3 (5.8)
     2,000-2,999 45 (17.9) 16 (35.6) 1 (2.2)
     3,000-4,999 43 (17.1) 16 (37.2) 2 (4.7)
     ≥5,000 42 (16.7) 17 (40.5) 2 (4.8)
    Employment status4 0.67 0.93
     Unemployed 117 (46.4) 53 (45.3) 7 (6.0)
     Non-precarious employment 45 (17.9) 21 (46.7) 2 (4.4)
     Precarious employment 78 (31.0) 29 (37.2) 3 (3.8)
     Self-employed 11 (4.4) 5 (45.5) 1 (9.1)
     Unpaid family worker 1 (0.4) 0 (0.0) 0 (0.0)
    Residential area4 0.43 0.22
     Seoul metropolitan city 104 (40.9) 49 (47.1) 4 (3.8)
     Other metropolitan cities5 42 (16.5) 15 (35.7) 1 (2.4)
     Other cities and counties 108 (42.5) 45 (41.7) 9 (8.3)
    Data collection 0.07 0.15
     Healthcare institutions 127 (48.5) 48 (37.8) 7 (5.5)
     The Korean Queer Culture Festivals (Seoul, Daegu) 22 (8.4) 14 (63.6) 3 (13.6)
     Online/offline transgender communities 113 (43.1) 50 (44.2) 4 (3.5)
    Table 1. Gender identity measured with a two-step method1

    Modified from Reisner et al. Lancet 2016;388:412-436 [4].

    Cisgender defined as a non-transgender whose legal sex at birth is in accordance with their current gender identity.

    Table 2. Distribution of study population and prevalence of gender identity spectrum by socio-demographic characteristics among transgender adults in Korea

    Values are presented as number (%).

    KRW, Korean won.

    Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

    p-value of the chi-square test comparing prevalence of gender identity spectrum across sociodemographic groups.

    Not all study participants provided this information; Number of non-responses: educational level (n=24), annual household income (n=26), employment status (n=25), and residential area (n=23).

    Included Sejong metropolitan autonomous city.

    Table 3. Distribution of study population and prevalence of transition-related healthcare by socio-demographic characteristics among transgender adults in Korea

    Values are presented as number (%).

    GID, gender identity disorder; KRW, Korean won.

    Not all study participants answered each question; Number of respondents diagnosed with GID who provided: educational level (n=233), annual household income and employment status (n=232), and residential area (n=234).

    p-value of the chi-square test comparing the prevalence of being or not being diagnosed with GID across different sociodemographic groups.

    Not all study participants answered each question; Number of respondents who received hormone therapy who provided: educational level (n=225), annual household income (n=223), employment status (n=225), and residential area (n=226).

    p-value of the chi-square test comparing the prevalence of receiving or not receiving hormone therapy across different sociodemographic groups.

    Not all study participants answered each question; Number of respondents who had at least one sex reassignment surgery who provided: educational level and annual household income (n=108), employment status (n=106), and residential area (n=108).

    p-value of the chi-square test comparing the prevalence of having or not having sex reassignment surgery across different sociodemographic groups.

    Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

    Not all study participants provided this information; Number of non-responses: educational level (n=24), annual household income (n=26), employment status (n=25), and residential area (n=23).

    Included Sejong metropolitan autonomous city.

    Table 4. Experience of diagnosis with GID and reasons for not pursuing GID diagnosis

    Values are presented as number (%).

    GID, gender identity disorder.

    Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

    Respondents could select multiple choices.

    Table 5. Experience of hormone therapy and reasons for not currently receiving hormone therapy

    Values are presented as number (%).

    Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

    Respondents could select multiple choices.

    Table 6. Experience of, routes to, and reasons for purchasing hormone medications without a prescription

    Values are presented as number (%).

    Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

    Respondents could select multiple choices.

    Table 7. Experience of sex reassignment surgery and reasons for not having sex reassignment surgery

    Values are presented as number (%).

    Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

    Respondents could select multiple choices.

    10,000 Korean won.

    Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

    Values are presented as number (%).

    KRW, Korean won.

    p-value of chi-square test comparing prevalence of delaying or avoiding hospital visits across sociodemographic groups.

    p-value of chi-square test comparing prevalence of being denied healthcare services across sociodemographic groups.

    Gender identity spectrum included transfeminine (transwomen and non-binary men) and transmasculine (transmen and non-binary women).

    Not all study participants provided this information. Number of non-responses: educational level (n=9), household income (n=11), employment status (n=10), and residential area (n=8).

    Included Sejong metropolitan autonomous city.

    Table 1.

    Table 2.

    Table 3.

    Table 4.

    Table 5.

    Table 6.

    Table 7.

    Epidemiol Health : Epidemiology and Health
    © Korean Society of Epidemiology.
    TOP